: It is currently viewed as a lead candidate for the next phase of preclinical testing due to its high metabolic stability and ability to suppress tumor growth at low doses. 2. Automotive & Industrial Parts
: This compound has shown up to 50 times higher efficacy than conventional chemotherapy drugs like paclitaxel in certain resistant cell models. 121606
: Research published in iScience and Frontiers in Pharmacology indicates that SB-T-121606 is a promising candidate for treating aggressive and drug-resistant cancers, such as pancreatic ductal adenocarcinoma and resistant ovarian carcinomas . : It is currently viewed as a lead
The most prominent modern reference for is in the development of third-generation taxanes , specifically the compound SB-T-121606 . specifically the compound SB-T-121606 .